Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Genuv Teams With Aiforia to Create an AI-Powered Version of its ATRIVIEW Drug Screening Platform

ATRIVIEW AI Platform Enables Faster and More Consistent Screening of Molecules That Demonstrate Neuroprotective and Neurogenerative Effects

Genuv, Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and developing advanced antibody therapies, announced an agreement with the medical technology company Aiforia Technologies Plc, to add Aiforia’s AI deep learning for medical image analysis to its ATRIVIEW discovery platform.

“We’re excited to help Genuv extend the capabilities of the remarkable ATRIVIEW® platform with the help of our powerful, deep learning technology”

The new version, ATRIVIEW® AI, will seamlessly incorporate Aiforia’s deep learning artificial intelligence technology to speed and automate image analysis within Genuv’s ATRIVIEW drug discovery platform. ATRIVIEW® AI will enable faster drug discovery and simultaneous analysis of multiple biomarkers.

Recommended AI News: Public Service Company of Oklahoma Selects ICF for Energy Efficiency Contract

“Aiforia is helping Genuv bring the power of deep learning artificial intelligence to our unique ATRIVIEW® drug discovery platform,” said Sungho Han, Ph.D., founder and CEO of Genuv. “The additional speed will enable Genuv and our partners to bring more drug candidates to the clinic more quickly.”

Related Posts
1 of 40,299

ATRIVIEW® is Genuv’s proprietary drug discovery platform. It is used to screen both existing drugs and new substances for neuroprotective and neurogenerative effects. Genuv’s lead drug candidate, SNR1611, was discovered with ATRIVIEW®. SNR1611 has been shown to restore CNS functions in preclinical models of amyotrophic lateral sclerosis (ALS) and Alzheimer’s Disease. It is now being studied in a Phase1/2a clinical trial for ALS.

Aiforia’s image analysis tools are used by many major pharmaceutical and biotechnology firms, including Sanofi, Boehringer Ingelheim, AstraZeneca and Bristol Myers Squibb, to help translate images into discoveries, decisions and diagnoses. Aiforia frees scientists and researchers from laborious manual tasks such as counting individual cells in diagnostic images.

Recommended AI News: Bardasz Announces New Website Launch

The partnership with Genuv marks the first time Aiforia’s technology is being used in neuroscience drug discovery for neurodegenerative diseases such as ALS and Alzheimer’s disease.

“We’re excited to help Genuv extend the capabilities of the remarkable ATRIVIEW® platform with the help of our powerful, deep learning technology,” said Jukka Tapaninen, CEO of Aiforia Technologies Plc. “Aiforia brings increased efficiency and precision to medical image analysis in fields including neuroscience. ATRIVIEW® is a powerful approach to the enormous unmet need in neurodegenerative diseases and we are humbled to be a part of this collaboration.”

Recommended AI News: Metamall Prepares For listing, Launches First of Its Kind Decentralized Metaverse Mall

[To share your insights with us, please write to]

Comments are closed.